Literature DB >> 10379339

Retroperitoneal germ cell tumor treated by PVeBV chemotherapy: a case report.

H Abe1, T Tani, H Naitoh, M Kodama.   

Abstract

The extragonadal germ cell tumor are uncommon neoplasms which account for only 1-5% of germ cell tumors, and its prognosis is poor. We report here the use of combination chemotherapy with cisplatin, etoposide, bleomycin, and vinblastine (PVeBV) for the treatment of retroperitoneal germ cell tumor. A 28-year-old male with complaints of abdominal pain and lumbago, without any abnormality in both testes by physical and ultrasonographic examination, showed retroperitoneal tumor by abdominal computed tomography. The serum alpha-fetoprotein and lactate dehydrogenase were elevated. The retroperitoneal tumor was treated surgically. The pathological diagnosis was mixed germ cell tumor. The lung and supraclavicular lymph node metastases disappeared completely after 3 courses of PVeBV chemotherapy with cisplatin (40 mg/m2 per day) and etoposide (100 mg/m2 per day) for 5 consecutive days, with vinblastine (0.2 mg/kg) on day 1, and bleomycin (30 mg/body) given on days 1, 8, and 15. Granulocyte colony-stimulating factor and serotonin receptor antagonist application were available on acute phase toxic effects. The patient is now alive and well, without recurrence, more than 26 months after the operation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10379339     DOI: 10.1093/jjco/29.5.261

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  2 in total

Review 1.  Imaging of leiomyosarcoma of the inferior vena cava: comparison of 2 cases and review of the literature.

Authors:  Barbara Sessa; Elsa Iannicelli; Salvatore Caterino; Francesco D'Angelo; Massimo Milione; Vincenzo Ziparo; Vincenzo David
Journal:  Cancer Imaging       Date:  2010-03-16       Impact factor: 3.909

2.  Isolated retroperitoneal mixed germ cell tumor presenting as acute abdomen - case report.

Authors:  Piotr Misiak; Lukasz Piskorz; Sławomir Jabłoński; Jacek Mikosiński; Marian Brocki; Szymon Wcisło
Journal:  Contemp Oncol (Pozn)       Date:  2013-03-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.